Vivani Medical is developing a small implant intended to help people maintain weight loss achieved with GLP-1 medicines. The approach uses semaglutide, the active ingredient in Novo Nordisk’s obesity drug Wegovy and its diabetes treatment Ozempic. Reporting from CNBC says Novo Nordisk has signed a pact with Vivani tied to the development of the long-acting implant, which is designed to address adherence challenges for patients using GLP-1 therapies.
Other coverage notes that the company is evaluating the implant as a potential option for longer-term maintenance rather than only initial weight-loss induction. One report describes the implant as potentially lasting up to a year, indicating the product is positioned as a sustained-delivery alternative to repeated injections. In parallel, the partnership is framed as a new bet on extending the duration and convenience of semaglutide therapy.
Across sources, the common focus is on product development and evaluation: a semaglutide-based GLP-1 implant, developed by Vivani with Novo Nordisk involvement, aimed at improving the ability of patients to sustain weight-loss results over time.
